The Sustained Release Pill Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is distributed as a pre-coated multiparticulate veterinary active pharmaceutical ingredient designated SRV-API-200. Two physical grades are assigned: SRV-API-200O for oral solids and feed premixes, and SRV-API-200S for sterile injectable suspensions. The oral grade is an off-white free-flowing powder with an ethylcellulose and ammonio methacrylate copolymer Type B membrane of 8–14 µm thickness; the injection grade is a terminally sterilized micronized powder intended for aqueous suspension. Release from both grades is diffusion-dependent and pH-independent across pH 1.2–6.8. Batch release specifications require assay 98.0–102.0% on dried basis by HPLC per USP <621>, total related substances ≤1.0%, individual related substances ≤0.2%, moisture ≤5.0% for oral grade and ≤3.0% for injection grade, residue on ignition ≤0.1%, and elemental impurities conforming to USP <232> and USP <233> with lead ≤5 ppm, cadmium ≤5 ppm, arsenic ≤2 ppm, and mercury ≤1 ppm. Residual solvents are controlled under USP <467> Option 2, with methanol ≤3000 ppm, acetone ≤5000 ppm, ethyl acetate ≤5000 ppm, and dichloromethane ≤600 ppm. The powder is supplied in 5 kg and 25 kg double LDPE bags containing desiccant, with re-test 24 months at 15–25°C.

What Limits Direct Compression Utility in Multi-Component Premixes?

For direct compression, SRV-API-200O requires a bimodal particle distribution to balance flow and compactability. The oral grade is specified with D10 20–40 µm, D50 80–150 µm, and D90 ≤250 µm by laser diffraction under EP 2.9.31; bulk density is 0.45–0.65 g/mL and tapped density 0.55–0.75 g/mL. Powder flow per EP 2.9.36 remains in the acceptable range when Hausner ratio is 1.10–1.30 and Carr index is 10–23%. In a 16-station rotary tablet press operated at 40 rpm, acceptable tablets are produced at 8–15 kN compression force when the formulation contains 25–35% w/w SRV-API-200O, lactose monohydrate D11, and 0.5% w/w magnesium stearate. Compression above 18 kN fractures the ethylcellulose membrane, increasing first-hour dissolution by more than 10% in USP <711> Apparatus 2, 900 mL, pH 6.8 phosphate buffer, 50 rpm. Direct compression utility is therefore limited by a narrow compression window of ±5 kN around 12 kN; outside this range tablet friability or release acceleration occurs. Premix blending requires a tumble blender operated at 20 rpm for 15 min, with stratified sampling confirming API content uniformity 90.0–110.0% of label claim. Segregation risk increases when the D50 of the premix excipient exceeds 500 µm.

Unlike unmodified veterinary active powders that release more than 85% within 15 min in 0.1 M HCl, SRV-API-200O limits Q2h to 15–35% across media at pH 1.2, 4.5, and 6.8. The pH-independent profile reduces inter-animal variability arising from gastrointestinal pH differences between monogastric and ruminant species. Compared with physical blends of active and release-retardant excipients, the pre-coated multiparticulate construction prevents segregation during shipping and dry feeding. Dose-dumping resistance under alcohol challenge is specified as not more than 15% release increase in 40% v/v ethanol dissolution medium over 2 h, whereas unmodified immediate-release formulations may exceed 90% release within 30 min under the same condition.

For capsules, SRV-API-200O is wet granulated using 5% w/w povidone K30 in isopropanol, dried at 40°C, and filled into size 0 or size 1 hard gelatin capsules at 200–400 mg fill weight. Capsule formulations use 10–25% w/w API; dissolution is measured in 900 mL phosphate buffer pH 6.8 with USP <711> Apparatus 2 at 100 rpm using sinkers. Powder formulations for oral drench or feed application are dry blends with lactose monohydrate, colloidal silicon dioxide, and flavor masking; the blend must pass through a 40-mesh screen to prevent segregation.

Sustained-Release Matrix Kinetic Parameters for Ruminant Bolus and Companion Animal Dosage Forms

Matrix systems are prepared by melt granulation with glyceryl behenate and high-viscosity hypromellose K100M. A twin-screw extruder with L/D 25:1 is set to barrel temperatures 55–62°C; the processing window is not wider than ±5°C because glyceryl behenate converts from α to β′ polymorph near 65°C, reducing matrix tortuosity and accelerating release. Screw speed 150–200 rpm and feed rate 8–12 kg/h produce granules with D50 180–240 µm. Tablets and boluses compressed at 30–50 kN from 40% w/w granules show erosion-controlled release after an initial lag phase. The release curve under USP <711> is typically controlled to Q2h 15–35%, Q4h 40–65%, and Q8h 70–90%. A dog model cited in the technical file showed tmax delayed from 1.5 h to 6–8 h and relative bioavailability 82–91% compared with an immediate-release oral suspension. For ruminant boluses, density is increased with 10–20% w/w iron powder to achieve mass 25–40 g and rumen retention. Published data for this specific configuration in food-producing species is limited, and withdrawal periods remain active-dependent.

Sterile injectable sustained-release processing begins with SRV-API-200S. The injection grade is a white, terminally sterilized powder with D50 5–15 µm, D99 ≤20 µm, endotoxin ≤0.5 EU/mg by USP <85>, sterility conforming to USP <71>, and particulate matter meeting USP <788> for small-volume injections. Reconstitution in 0.9% w/v sodium chloride or 2.5% w/v sodium carboxymethylcellulose vehicle yields viscosity 12–18 mPa·s at 20°C. Injectability through a 21G needle requires D99 not exceed 20 µm. Gamma sterilization at 25 kGy is acceptable; autoclaving above 121°C is not recommended because the methacrylic film undergoes phase separation, and Q2h shifts above 60%. Emulsion or oil-vehicle formulations should avoid amine-based stabilizers such as tromethamine; residual ester groups in the copolymer undergo aminolysis and alter release onset. Intramuscular depot suspensions are administered at 2–5 mL per injection site, with depot volume selected according to species muscle mass.

When Climatic Zone IVb Conditions Challenge Premix and Granule Physical Stability

Premix and granule preparations containing SRV-API-200O are packaged in heat-sealed aluminum foil with 10 g silica gel desiccant per 1 kg. Zone IVb stability is assessed at 30°C ± 2°C / 75% RH ± 5% RH per ICH Q1A(R2). Moisture ingress above 5.0% in microcrystalline cellulose carriers depresses the glass transition of the methacrylate film, increasing Q2h by 8–12%. High-shear granulation with 2.0% w/w sodium carboxymethylcellulose binder reaches wet mass torque 18–22 N·m in a 10 L granulator; post-drying at 50°C to residual moisture ≤2.0% is mandatory before blending with SRV-API-200O. Oral powders and solutions for drinking water require a suspending vehicle with 0.15% w/w xanthan gum and 0.05% w/w polysorbate 80; shear-thinning viscosity at 10 s⁻¹ should remain 150–250 mPa·s. In high-humidity granule packaging, anti-caking agents such as colloidal silicon dioxide are included at 0.5–1.0% w/w.

Granule and premix manufacturing uses a fluid-bed granulator with top-spray nozzle at inlet air temperature 50–60°C. Spray rate is set to 10–20 g/min per 1 kg batch to avoid overwetting of the ethylcellulose coat. Drying endpoint is determined by loss-on-drying ≤2.0% at 85°C using USP <731>. Electrostatic adhesion at relative humidity below 30% RH is controlled by grounding the granulator filter housing and maintaining ground resistance below 10⁶ Ω.

Residual solvent control uses USP <467> Option 2; limits for methanol ≤3000 ppm, acetone ≤5000 ppm, dichloromethane ≤600 ppm, and ethyl acetate ≤5000 ppm are assigned because these solvents are used in the polymer coating step. Water determination by USP <921> uses Karl Fischer titration with formamide as solubilizer; moisture is limited because esterified methacrylic polymers are hydrolytically labile above 60% RH. Bulk material stored in unopened containers at 15–25°C has a re-test period of 24 months; after opening, use within 90 days is required.

Because the methacrylic ester side groups are susceptible to aminolysis, the product is incompatible with strong oxidizing agents and with amine-based additives. Pre-drying is required when ambient relative humidity exceeds 60% RH. For sterile suspensions, reconstitution must occur under ISO 5 laminar airflow, and the suspension should be used within 24 h if stored at 2–8°C. Withdrawal periods for food-producing species are not assigned by the product grade alone; they are determined by the approved residue file for the active moiety and by the route of administration. The material is not intended for use where the active pharmaceutical ingredient has not been authorised for the target species.